Literature DB >> 33599206

Role of percutaneous radiological treatment in biliary complications associated with adult left lobe living donor liver transplantation: a single-center experience.

Sinan Karatoprak1, Ramazan Kutlu1, Sezai Yılmaz2.   

Abstract

PURPOSE: Biliary complications develop at a higher rate in living donor liver transplantation (LDLT) compared with cadaveric liver transplantation. Almost all studies about biliary complications after LDLT were made with the right lobe. The aim of this study was to determine the frequency of biliary complications developing after adult left lobe LDLT and to evaluate the efficacy of the algorithm followed in diagnosis and treatment, particularly percutaneous radiological treatment.
METHODS: A total of 2185 LDLT operations performed in our center between May 2009 and December 2019 were retrospectively reviewed and patients receiving left lobe LDLT were analyzed regarding biliary complications and treatments. Biliary complications were treated via percutaneous drainage under ultrasound (US) guidance, endoscopic retrograde cholangiopancreatography (ERCP), and percutaneous transhepatic cholangiography (PTC)/ percutaneous transhepatic biliary drainage (PTBD). Patient demographics, ERCP procedures before percutaneous treatment, and percutaneous treatment indications were analyzed.
RESULTS: A total of 69 adult patients received left lobe LDLT. Biliary complications requiring endoscopic and/or percutaneous treatment developed in 28 patients (40%). Of these patients, 4 had bile leakage (14%), 20 had anastomosis stricture (72%), and 4 had both leakage and anastomosis stricture (14%). External drainage treatment under ultrasound guidance was sufficient for 2 of 4 patients with bile leakage, and these cases were accepted as minor bile leakage (7%). Overall, 26 patients underwent ERCP; of these, 8 were referred for PTC/PTBD because the guidewire and/or balloon-stent could not pass the anastomosis stricture (n=7) and common bile duct cannulation could not be obtained because of duodenal diverticulum (n=1). Diagnostic PTC was performed in 10 patients, 8 were referred after inadequate/failed ERCP procedure and two were referred directly without ERCP. Anastomosis stricture was found in 7 patients and anastomosis stricture and bile leakage in 3. In 7 patients determined to have stricture, balloon dilatation was applied and then biliary drainage was performed. In 3 patients who had leakage and anastomosis stricture, balloon dilatation was applied for stricture; after dilatation, an IEBD catheter was placed through the leakage region in 2 patients, while a covered metallic stent passing through the leakage region was placed in one patient.
CONCLUSION: Generally, ERCP is the first preferred method in biliary complications of LDLT; however, in cases where a response cannot be obtained by endoscopic treatment or require complex and/or aggressive treatment, percutaneous radiological treatment should be the treatment of choice before surgery in left lobe LDLT.

Entities:  

Year:  2021        PMID: 33599206      PMCID: PMC8289434          DOI: 10.5152/dir.2021.20523

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  26 in total

1.  Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline.

Authors:  J-M Dumonceau; A Tringali; D Blero; J Devière; R Laugiers; D Heresbach; G Costamagna
Journal:  Endoscopy       Date:  2012-02-01       Impact factor: 10.093

2.  Bile duct strictures after liver transplantation: a changing landscape of the Achilles' heel.

Authors:  Baburao Koneru; Mark J Sterling; Phillip F Bahramipour
Journal:  Liver Transpl       Date:  2006-05       Impact factor: 5.799

3.  Biliary strictures following liver transplantation: past, present and preventive strategies.

Authors:  Sharad Sharma; Ahmet Gurakar; Nicolas Jabbour
Journal:  Liver Transpl       Date:  2008-06       Impact factor: 5.799

Review 4.  Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience.

Authors:  Vincenzo Mazzaferro; Sherrie Bhoori; Carlo Sposito; Marco Bongini; Martin Langer; Rosalba Miceli; Luigi Mariani
Journal:  Liver Transpl       Date:  2011-10       Impact factor: 5.799

5.  Percutaneous transhepatic biliary drainage in patients with postsurgical bile leakage and nondilated intrahepatic bile ducts.

Authors:  E A de Jong; A Moelker; T Leertouwer; S Spronk; M Van Dijk; C H J van Eijck
Journal:  Dig Surg       Date:  2014-01-14       Impact factor: 2.588

6.  Living related liver transplantation in adults.

Authors:  S Kawasaki; M Makuuchi; H Matsunami; Y Hashikura; T Ikegami; Y Nakazawa; H Chisuwa; M Terada; S Miyagawa
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

7.  Liver transplantation using a right lobe graft from a living related donor.

Authors:  Y Yamaoka; M Washida; K Honda; K Tanaka; K Mori; Y Shimahara; S Okamoto; M Ueda; M Hayashi; A Tanaka
Journal:  Transplantation       Date:  1994-04-15       Impact factor: 4.939

8.  Complete transection of the main bile duct: minimally invasive treatment with an endoscopic-radiologic rendezvous.

Authors:  Fausto Fiocca; Filippo M Salvatori; Fabrizio Fanelli; Antonio Bruni; Vincenzo Ceci; Mario Corona; Gianfranco Donatelli
Journal:  Gastrointest Endosc       Date:  2011-10-01       Impact factor: 9.427

Review 9.  Left hepatectomy versus right hepatectomy for living donor liver transplantation: shifting the risk from the donor to the recipient.

Authors:  Garrett R Roll; Justin R Parekh; William F Parker; Mark Siegler; Elizabeth A Pomfret; Nancy L Ascher; John Paul Roberts
Journal:  Liver Transpl       Date:  2013-04-15       Impact factor: 5.799

10.  Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation.

Authors:  P A Clavien; C A Camargo; R Croxford; B Langer; G A Levy; P D Greig
Journal:  Ann Surg       Date:  1994-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.